KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Depreciation & Amortization (CF) (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $21.3 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.47% year-over-year to $21.3 million; the TTM value through Dec 2025 reached $91.0 million, up 15.53%, while the annual FY2025 figure was $91.0 million, 15.53% up from the prior year.
  • Depreciation & Amortization (CF) reached $21.3 million in Q4 2025 per PCRX's latest filing, up from $21.2 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $30.4 million in Q4 2022 and bottomed at $4.9 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $18.3 million, with a median of $19.8 million recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 326.06% in 2022, then crashed 39.21% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $13.1 million in 2021, then surged by 132.64% to $30.4 million in 2022, then tumbled by 39.21% to $18.5 million in 2023, then grew by 14.92% to $21.2 million in 2024, then grew by 0.47% to $21.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $21.3 million in Q4 2025, $21.2 million in Q3 2025, and $27.3 million in Q2 2025.